Who Paid My Doc
Hemlibra
Biological BioOncology
NDC 50242-920-01
General payments
$10,230
Research payments
$0
Through program year 2022, $10,230 in general payments and $0 in research payments were reported against Hemlibra (BioOncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | General | $10,230 | 5 |
Breakdown
Each share is of general payments naming this product in 2022.
Each share is of general payments naming this product to practitioners with a specialty in 2022. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2022 where a state was reported.
Given in the clinic
Part B · billing code| Billing code | Providers | Services | Paid by Medicare |
|---|---|---|---|
| Injection, emicizumab-kxwh, 0.5 mg J7170 | 7 | 1,367,382 | $54,620,684 |
Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.
Records
5 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.